Connecting Psychiatry - Expert community for all mental health professionals

(PSYCHIATRIC TIMES) - MedPage Today Action Points

NEW YORK, Jan. 18 -- Gauging the winds of medical advances is an iffy proposition at best, but for psychiatrists the new year is likely to bring much-anticipated data on the safety and efficacy of antipsychotic and bipolar medications in children and adolescents.

With pediatric safety and efficacy data lacking for most drugs used to treat schizophrenia and bipolar disorder, use of these drugs in pediatric patients is more off-label than on-label, noted Christoph U. Correll, of the Albert Einstein College of Medicine in the Bronx. Dr. Correll is also a member of the American Academy of Child and Adolescent Psychiatry (AACAP).

For full article, please visit:

Views: 8


You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds

psychiatryRounds Social Media


CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2020   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service